Your browser doesn't support javascript.
loading
Exploiting the preferential phagocytic uptake of nanoparticle-antigen conjugates for the effective treatment of autoimmunity.
Sadanandan, Prashant; Payne, Natalie L; Sun, Guizhi; Ashokan, Anusha; Gowd, Siddaramana G; Lal, Arsha; Satheesh Kumar, Madathiparambil Kumaran; Pulakkat, Sreeranjini; Nair, Shantikumar V; Menon, Krishnakumar N; Bernard, Claude C A; Koyakutty, Manzoor.
Afiliação
  • Sadanandan P; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India; Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Payne NL; Australian Regenerative Medicine Institute, Monash University, Clayton, Australia.
  • Sun G; Australian Regenerative Medicine Institute, Monash University, Clayton, Australia.
  • Ashokan A; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Gowd SG; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Lal A; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Satheesh Kumar MK; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Pulakkat S; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Nair SV; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Menon KN; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. Electronic address: krishnakumarmenon@aims.amrita.edu.
  • Bernard CCA; Australian Regenerative Medicine Institute, Monash University, Clayton, Australia. Electronic address: claude.bernard@monash.edu.
  • Koyakutty M; Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. Electronic address: manzoork@gmail.com.
Nanomedicine ; 40: 102481, 2022 02.
Article em En | MEDLINE | ID: mdl-34748963
ABSTRACT
Tolerance induction is central to the suppression of autoimmunity. Here, we engineered the preferential uptake of nano-conjugated autoantigens by spleen-resident macrophages to re-introduce self-tolerance and suppress autoimmunity. The brain autoantigen, myelin oligodendrocyte glycoprotein (MOG), was conjugated to 200 or 500 nm silica nanoparticles (SNP) and delivered to the spleen and liver-resident macrophages of experimental autoimmune encephalomyelitis (EAE) mice, used as a model of multiple sclerosis. MOG-SNP conjugates significantly reduced signs of EAE at a very low dose (50 µg) compared to the higher dose (>800 µg) of free-MOG. This was associated with reduced proliferation of splenocytes and pro-inflammatory cytokines secretion, decreased spinal cord inflammation, demyelination and axonal damage. Notably, biodegradable porous SNP showed an enhanced disease suppression assisted by elevated levels of regulatory T cells and programmed-death ligands (PD-L1/2) in splenic and lymph node cells. Our results demonstrate that targeting nano-conjugated autoantigens to tissue-resident macrophages in lymphoid organs can effectively suppress autoimmunity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalomielite Autoimune Experimental / Nanopartículas / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalomielite Autoimune Experimental / Nanopartículas / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article